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ABSTRACT
The post-translational modification poly(ADP-
ribosyl)ation (PARylation) plays key roles in genome
maintenance and transcription. Both non-covalent
poly(ADP-ribose) binding and covalent PARylation
control protein functions, however, it is unknown
how the two modes of modification crosstalk
mechanistically. Employing the tumor suppressor
p53 as a model substrate, this study provides
detailed insights into the interplay between non-
covalent and covalent PARylation and unravels
its functional significance in the regulation
of p53. We reveal that the multifunctional C-
terminal domain (CTD) of p53 acts as the central
hub in the PARylation-dependent regulation of
p53. Specifically, p53 bound to auto-PARylated
PARP1 via highly specific non–covalent PAR-CTD
interaction, which conveyed target specificity
for its covalent PARylation by PARP1. Strikingly,
fusing the p53-CTD to a protein that is normally
not PARylated, renders this a target for covalent
PARylation as well. Functional studies revealed
that the p53–PAR interaction had substantial
implications on molecular and cellular levels.
Thus, PAR significantly influenced the complex
p53–DNA binding properties and controlled
p53 functions, with major implications on the
p53-dependent interactome, transcription, and
replication-associated recombination. Remarkably,
this mechanism potentially also applies to other
PARylation targets, since a bioinformatics analysis
revealed that CTD-like regions are highly enriched in
the PARylated proteome.
INTRODUCTION
Genotoxic stress constantly harms mammalian cells and
contributes to severe pathological states, such as cancer,
aging, and neurodegenerative diseases. To ensure genome
integrity and physiological homeostasis throughout the
lifetime of an organism, multiple DNA damage response
and repair mechanisms have evolved during evolution.
In mammals, two key players in these processes are the
‘caretaker of the genome‘ poly(ADP-ribose) polymerase 1
(PARP1) and the ‘guardian of the genome’ p53.
PARP1 acts as a sensor, transducer and effector
within the DNA damage response with a wide spectrum
of functions in several DNA repair mechanisms as
well as in chromatin remodeling, transcription, energy
metabolism, and regulation of cell death. Using NAD+
as a substrate, PARP1 catalyzes the formation of the
post-translational PARylation by covalently attaching
PAR chains at glutamate, aspartate, lysine, arginine
and serine residues of acceptor proteins (1,2). The
resulting biopolymer, i.e., poly(ADP-ribose) (PAR), is
a highly negatively charged nucleic-acid-like molecule.
Apart from covalent PARylation, proteins can ‘read’
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PARylation by binding non-covalently to PAR, which
has emerged as a key mechanism to regulate protein
function, localization, stability, as well as interactions
with other macromolecules such as DNA and RNA.
Several PAR-bindingmodules were identified, including the
PAR-binding motif (PBM), the PAR-binding zinc finger
motif (PBZ), the macrodomain, and the WWE domain
(3). The PBM was described as a weakly conserved 20-
amino acid (aa) consensus sequence comprising a region
rich in basic aa and a core pattern of hydrophobic aa
interspersed with basic residues. So far, no defined protein
fold was assigned to the PBM, which is present in hundreds
of proteins, including p53, XPA, p21, XRCC1, TERT
and histones (4,5). Interestingly, PAR binding proteins
are very often also acceptors of covalent PARylation,
however the molecular relationship and the mechanistic
interplay between the twomodes of modification are largely
unknown.
The tumor suppressor protein p53 also acts as a master
regulator in many DNA damage response mechanisms.
Inactivation of p53 is an important driving force of
carcinogenesis, as p53 is mutated in >50% of human
cancers. This renders the TP53 gene the most prominent
target for tumorigenic mutations (6). DNA damage
triggers p53 stabilization via its phosphorylation and
the subsequent release from its suppressor MDM2. In
response, p53 acts as a transcription factor and induces the
expression of a wide spectrum of genes involved in cell cycle
regulation, apoptosis, and DNA repair (7). p53 comprises
an N-terminal transactivation domain (TAD), a DNA
binding domain (DBD), a tetramerization domain (TD),
and a multifunctional C-terminal domain (CTD) (Figure
1A). The CTD, which is highly basic and intrinsically
disordered, participates in all aspects of p53 functions,
including transcriptional activity, regulation of protein
stability, recruitment of co-factors, and its complex binding
behavior to DNA (8). Mice carrying a genetic deletion
of the CTD exhibit anemia and bone marrow failure,
suggesting crucial functions for this region in organismic
physiology (9,10). However, the exact role of the CTD in
p53 regulation is still controversial. Initial studies reported
that the CTD is a negative regulator of sequence-specific
DNA binding (11). Later, the CTD was described to
have positive regulatory properties, such as facilitating p53
binding to chromatin and long, ‘naked’ DNA stretches (12)
as well as sliding along DNA, while searching for cognate
binding sites (13,14). Moreover, the CTD controls the
stability of p53–DNA complexes by facilitating cooperative
contacts between the core DNA binding domains of p53
(15). Most aa of the CTD are targeted by post-translational
modifications (PTMs), such as acetylation, ubiquitination,
SUMOylation, neddylation or methylation, all of which are
vital for p53 activity and stability, depending on the specific
cellular conditions (8).
p53 and PARP1 interact at multiple levels; thus, a
direct protein-protein interaction was found in vitro and
in cells (16,17). Consistently, p53 is a substrate for
covalent poly(ADP-ribosyl)ation (PARylation), which has
been demonstrated in vitro as well as in cells (18–20).
Apart from covalent PARylation, p53 also displays a non-
covalent high-affinity interaction with PAR (21,22). Using
peptide studies, Malanga et al. reported three potential
PBMs within the p53 sequence (22), two of which are
located in the DBD (PBM 1&2) and another one in
the TD (PBM 3). Interestingly, p53 has a preference
for long PAR chains over short ones (21) and PAR
was shown to decrease the DNA binding affinity of p53
(22). In addition, it was reported in a murine system
that PARylation of p53 blocks the interaction between
p53 and the nuclear export receptor Crm1, resulting
in nuclear accumulation of p53 (23). Furthermore, p53
deletion in a Parp1 null genetic background accelerates the
onset and shortens the latency of mammary tumorigenesis
in mice (24). Despite these studies demonstrating a
significant relationship of PARylation and p53, many
open questions on the molecular and cellular mechanisms
of this interaction remain. In particular, similarly to
other PARylation substrates, the relationship between non-
covalent PAR binding and covalent PARylation of p53
is not understood. Furthermore, it is largely unknown
how PAR influences the biochemical properties of p53
and how this translates to a regulation of its cellular
functions. Beyond this, it is still enigmatic how PARP1
targets p53 and other proteins for covalent PARylation.
Here, we systematically searched for regions in p53 that are
essential for non-covalent PAR binding and for its covalent
PARylation. We identified a novel region in the p53-CTD
that is crucial for non-covalent PAR binding in full-length
(fl) p53 and that determines the covalent PARP1-mediated
PARylation of p53. Strikingly, fusing the p53-CTD to a
protein that is usually not PARylated renders this a target of
covalent PARylation as well. These results demonstrate that
in the case of p53, PAR binding and covalent PARylation
are inherently linked and that the multifunctional CTD
of p53 is the center for the regulation of p53 functions
by PARylation with implications on protein interactions,
transcription and replication-associated recombination.
MATERIALS AND METHODS
Bioinformatic analysis to identify CTD-like regions in
PARylated proteins
Protein sequences from the lists of covalently PARylated
proteins under genotoxic conditions were retrieved from
previous studies (25–27). The IUPred source code (28,29)
was modified and used to predict disordered domains in
these covalently PARylated proteins, applying the ‘long
disorder’ option. A protein region was assumed to be
intrinsically disordered, if a disorder tendency of >0.5
was present. The intrinsically disordered fragments were
screened for highly positively charged regions. A net charge
of at least +4 was chosen in a sliding window of 15 aa as
in-silico search pattern. If a directly consecutive region in a
protein was found, it was merged with the previous region.
To calculate the charge, the amount of basic aa, i.e., arginine
or lysine, were subtracted by the amount of acidic aa,
i.e., glutamate or aspartate. As control groups, the human
proteome (www.uniprot.org, proteome ID UP000005640,
reviewed, 20 169 proteins, last modified: 29 January 2017),
cytoplasmic proteins from the ‘Eukaryotic Subcellular
Localization DataBase’ (eSLDB, gpcr.biocomp.unibo.it/
esldb, 776 proteins) (30) or the database of N-glycosylated
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proteins (N-GlycosylDB, 1118 proteins) from the dbPTM
database (dbptm.mbc.nctu.edu.tw) (31) were used.
Protein purification
Human p53, mutants and truncation variants thereof were
expressed in Escherichia coli BL21(DE3). Expression was
induced at anOD600 of 0.6–0.8 with 20MIPTG, followed
by an incubation for 12 h at 16◦C and 4 h at 10◦C. After
centrifugation, cells were snap-frozen in liquid nitrogen.
Cells were thawed and resuspended in lysis buffer [50 mM
sodium phosphate pH 8.0, 300 mM NaCl, 10 mM 2-
mercaptoethanol, 10 mM imidazole, 1 mg/ml lysozyme, 1
× EDTA-free protease inhibitor cocktail (Roche)]. Cells
were sonicated, followed by DNA digestion with 5 g/ml
DNase I for 30 min. The insoluble fraction was removed by
centrifugation at 15,000 g for 30 min. The soluble fraction
was filtered and loaded on an A¨KTA chromatography
system (GEHealthcare), using a 1-ml HisTrap column (GE
Healthcare). Elution was performed with a linear gradient
from 10 mM to 500 mM imidazole in a buffer, consisting
of 50 mM sodium phosphate pH 8.0, 300 mM NaCl.
Elution fractions were dialyzed and thrombin-cleavage
was performed overnight for His-tag removal in a buffer,
consisting of 20 mM sodium phosphate pH 8, 150 mM
NaCl, 10 mM 2-mercaptoethanol. Thereafter, thrombin
was inhibited with 0.1 mg/ml Pefabloc (Roche). A second
purification step was performed with a HiTrap heparin HP
1-ml column (GE Healthcare), using a linear gradient from
150 mM to 1000 mMNaCl in a buffer, consisting of 20 mM
sodium phosphate pH 8.0.
p53 325–393 was expressed and purified as described
above, but the second purification step was performed with
a HiTrap SP HP 1-ml column (GE Healthcare), instead of
a heparin column.
GST-p53 325–393, GST-p53 359–387 or GST were
expressed and lyzed as described above, with a modified
lysis buffer (50 mM sodium phosphate pH 7.0, 300 mM
NaCl, 5 mM 2-mercaptoethanol, 1 mg/ml lysozmye, 1 ×
protease inhibitor cocktail (Roche)). To the cleared lysate 1
ml of glutathione sepharose 4B (GEHealthcare) was added
and incubated rotating for 2 h at 4◦C. Beads were washed
with 15 ml GST wash buffer 1 (50 mM sodium phosphate
pH 7.0, 300 mM NaCl) for 10 min, while rotating. After
centrifugation and removal of the supernatant, 7.5 ml GST
wash buffer 1 were added to the beads and the slurry
was poured into an empty gravity flow column. After
washing the column with 5 ml of GST wash buffer 1, 5
ml of GST wash buffer 2 (50 mM sodium phosphate pH
7.0, 150 mM NaCl) were added. Elution was performed
with 20 ml of 10 mM glutathione in GST wash buffer 2.
Purification of GST-DEK WT and GST-DEK PBM was
performed as described previously (32). GST-Af1521 was
expressed and purified according to a previous study (25).
The used plasmid DNA pGEX-4T1::Af1521 was received
from Michael L. Nielsen (University of Copenhagen,
Denmark). Human PARP1 was expressed in Sf9 cells
and purified as described previously (21). Snake venom
phosphodiesterase (PDE I) was purchased (Affymetrix)
and purified further according to a previous study (33).
For the thrombin cleavage assay, the p53 variants p53 28-
TCS-29, p53 68-TCS-69, p53 324-TCS-325, as well as
p53 WT were covalently PARylated to a larger extent
after nickel-affinity chromatography and dialysis. In-vitro
PARylation was performed in a solution, consisting of 20
mM sodium phosphate pH 8.0, 150 mM NaCl, 10 mM 2-
mercaptoethanol, 10 mM MgCl2, 7.7 g/ml self-annealed
oligonucleotide GGAATTCC, 23 nM rec. PARP1 and 154
MNAD+ for 1 h at RT. PARylated p53 was purified from
this solution with a HiTrap heparin HP 1-ml column, as
described above. For determination of PARylation sites by
mass spectrometry, p53 WT was purified and PARylated in
the sameway as described above, with the exception that the
His-tag was cleaved during dialysis.
PAR overlay assay
168–403 pmol of custom-synthesized peptides (Genscript)
or 5 pmol proteins were blotted on a nitrocellulose
membrane (GE Healthcare) either by slot-blotting or
by SDS-PAGE and semi-dry blotting, respectively. The
membrane was incubated in a solution containing 0.2 M
PAR (synthesized and purified as described previously (21))
in TBST buffer (150 mM NaCl, 10 mM Tris pH 8, 0.05%
Tween 20) for 1 h at RT, followed by three washes of 10 min
in TBST buffer, containing 1 MNaCl. PAR concentrations
refer always to ADP-ribose moieties. The membrane was
blocked in TBSMT (TBST with 5% skimmed milk) for 1
h and subsequently PAR was detected using the mouse
monoclonal 10H anti-PAR antibody (34) and a HRP-
coupled secondary antibody (Dako). Detection of p53 was
performed with the mouse monoclonal DO-1 antibody
(Merck). As loading control for slot-blotting, SYPRO ruby
staining (Thermofisher Scientific) was used directly after
blotting. Each PAR overlay experiment was performed at
least in 3 independent experiments.
PepSpot peptide arrays
PepSpots peptide arrays (JPT Peptide Technologies)
contained custom synthesized peptides with a length of
20 aa covalently linked to a cellulose membrane. Each
spot carried approximately 5 nmol of a peptide. A PAR
overlay assay was performed as described above with
the exception that Alexa488-coupled secondary antibody
(Thermofisher Scientific) was used. Fluorescence detection
was performed, using a Typhoon FLA 9500 biomolecular
imager (GE Healthcare). Ponceau S staining served as
loading control.
Electrophoretic mobility shift assay
A 1:2 dilution series of rec. human p53 was prepared in
a buffer, consisting of 25 mM Tris-HCl pH 7.4, 150 mM
NaCl, 5% (v/v) glycerol and 0.5 mMDTT. The highest p53
concentration was 7 M, the lowest 27.24 nM. 250 fmol
of a double-stranded, Cy5-labeled p53 response element
from the p21 promotor (REp21, Oligo 1+Oligo 2 annealed)
was added and incubated for 15 min at RT. 10 × loading
dye [250 mM Tris-HCl pH 7.4, 40% (v/v) glycerol, 0.2%
(w/v) Orange G] was added to a final volume of 10 l.
Samples were loaded on a 4% native TBE polyacrylamide
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gel in a Hoefer SE400 gel chamber, containing 0.5 × TBE
as running buffer. After 1 h with a voltage of 300 V,
fluorescence detection was performed, using a Typhoon
FLA 9500 biomolecular imager.
DNA-PAR competition assay
A 1:2 dilution series of non-fractionated, unlabeled PAR
was prepared (in concentrations of 200 M to 1.56 M).
p53 WT (1 M), p53 1–355 (1.5 M), p53 PBM4–4 (1
M) or p53 325–393 (18.7 M) were added to the PAR
solution and incubated for 10 min at RT in a buffer,
consisting of 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
2% (v/v) glycerol and 0.2 mM DTT. 250 fmol of a
double-stranded, Cy5-labeled p53 response element from
the p21 promotor (REp21, Oligo 1 + Oligo 2 annealed)
or a scrambled variant thereof (scrambled REp21, Oligo 4
+ Oligo 5 annealed) were added and incubated for 15
min at RT. 10 × loading dye (250 mM Tris-HCl pH 7.4,
40% (v/v) glycerol, 0.2% (w/v) Orange G) was added to
a final volume of 10 l. Samples were loaded on a 4%
native TBE polyacrylamide gel in a Hoefer SE400 gel
chamber, containing 0.5 × TBE as running buffer. After
applying a voltage of 300 V for 1 h, fluorescence detection
was performed, using a Typhoon FLA 9500 biomolecular
imager.
Differential scanning fluorimetry
To measure the melting temperature of p53, differential
scanning fluorimetry (DSF) was used, according to a
previous study (35). The total volume per sample comprised
25 l. To a buffer, consisting of 50 mM Tris-HCl pH 7.4,
150 mM NaCl and 1 mM DTT, rec. p53 variants were
added to a final concentration of 2.3 M. 50 M size-
fractionated PAR (concentration of ADP-ribose subunits)
of different chain length (size-fractionation as described
previously (21)) was added and incubated for 10 min at
RT. Next, a double-stranded p53 response element from
the p21 promotor (REp21, Oligo 2 + Oligo 3 annealed) was
added to a final concentration of 2.3 M (concentration
of double-stranded DNA chains), and incubated for 10
min at RT. 2.5 l of 100 × SYPRO Orange solution
(Thermofisher Scientific) was then added, followed by a
melt curve analysis with a temperature ramp from 20◦C to
95◦C at 1◦C/min steps, using a quantitative real-time CFX
connect thermocycler (Biorad).
In-vitro co-immunoprecipitation (coIP)
Rec. human PARP1 (1 g) was incubated with 10 g anti-
PARP1 antibody (FI-23) (36) or with mouse IgG control
(Santa Cruz) for 1 h at 4◦C in 300 l IP buffer (50 mMTris–
HCl pH7.4, 150mMNaCl, 1%NP-40, 0.5%deoxycholate).
10 l Protein G sepharose beads (Sigma-Aldrich) were
added and incubated for 2 h at 4◦C, while rotating.
Indicated samples were subjected to auto-PARylation of
PARP1 by adding 10 mM MgCl2, 7.7 g/ml self-annealed
oligonucleotide GGAATTCC, 1 mM DTT and 100 M
NAD+. Samples were incubated for 5 min at 4◦C, while
rotating. After centrifugation at 2400 g for 20 s, beads were
washed with 500 l wash buffer (50 mM Tris-HCl pH 7.4,
150 mMNaCl, 0.1%NP-40, 0.05% deoxycholate), followed
by a second washing step, using 250 l IP buffer. After
centrifugation and removal of the supernatant, 300 l IP
buffer were added, together with 1 mM DTT and 23 pmol
of rec. p53. Incubation took place for 1 h at 4◦C while
rotating. Beads were washed twice for 5 min in 500 l IP
buffer and once for 5 min in 500 l wash buffer while
rotating. Proteins were eluted from beads by adding 22 l
of 2 × SDS sample buffer, incubating 5 min at 95◦C and
subjected to SDS-PAGE followed by Western blotting. The
rabbit polyclonal anti-PARP1 antibody H250 (Santa Cruz)
and the rabbit polyclonal anti-p53 antibody FL-393 (Santa
Cruz) were used for immunodetection.
In-vitro PARylation assay
Unless stated otherwise, 0.5Mrec. protein was PARylated
in PBS buffer, in presence of 10 mMMgCl2, 7.7 g/ml self-
annealed oligonucleotideGGAATTCC, 1mMDTT, 23 nM
rec. PARP1 and 100 M NAD+, in a final volume of 10
l for 1 h at RT. Proteins were separated by 15% SDS-
PAGE, followed by semi-dry blotting on a nitrocellulose
membrane (GE Healthcare) and immunodetection using
the anti-PAR antibody 10H, unless stated otherwise. Each
in-vitro PARylation experiment was performed at least in
three independent experiments.
Thrombin cleavage assay
Rec. protein (5 pmol, unless stated otherwise) was incubated
in a buffer, containing 20 mM sodium phosphate pH
8.0, 100 mM NaCl, 10 mM 2-mercaptoethanol. 1 unit
thrombin was added to a final volume of 30 l and
incubation was performed for 16 h. Thrombin cleavage was
stopped by addition of SDS sample buffer and samples
were subjected to SDS-PAGE, using a 15% acrylamide gel,
followed by semi-dry blotting and immunodetection. Each
thrombin cleavage experiment was performed at least in
three independent experiments.
Analytical size-exclusion chromatography
The tetramerization of p53 variants was analyzed by
size exclusion chromatography (SEC). The tetramerization
deficient mutant p53 L344P was used as a control. SEC
was performed in 50 mM Tris-HCl pH 7.4 and 150 mM
NaCl at a flow rate of 0.03 ml/min using a Superose
6 Increase column (GE healthcare). 30 l of 8 M
protein solution were loaded respectively and elution was
analyzed by absorbance measurement at 280 nm. Sizes
were calculated by a gel filtration HMW calibration kit
(GE Healthcare). To analyze DNA and PAR binding, p53
variants were preincubated with 0.25 M double-stranded
response element from the p21 promotor (REp21, Oligo 2
+ Oligo 3 annealed) or 50 M unfractionated PAR for 10
min and elution was followed by absorbance measurements
at 258 nm.
Mass spectrometric identification of PARylation sites
Sample treatment and mass spectrometer analyses were
performed as described previously (33). Briefly, PARylated
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proteins were treated with PDE I overnight at 25◦C. The
samples were reduced with DTT for 30 min at 56◦C and
alkylatedwith chloroacetamide for 60min atRT.Digestions
were performed using trypsin or pepsin for 4 h at 37◦C.
Digested samples were analyzed by reversed phase liquid
chromatography nanospray tandem mass spectrometry
(LC–MS/MS) using an Eksigent nano-HPLC equipped
with a C18 LC column (5 m, 100 A˚ pore size) in a silica
capillary (Acclaim PepMap100, Thermofisher Scientific).
After sample injection, the column was washed for 5 min
with 100% mobile phase A (0.1% formic acid) and peptides
were eluted using a linear gradient of 10% mobile phase
B to 40% mobile phase B in 35 min, then to 80% B in
an additional 5 min, at 300 nl/min. The LTQ-Orbitrap
mass spectrometer (Thermofisher Scientific) was operated
in a data dependent mode in which each full MS scan
(30 000 resolving power) was followed by 5 MS/MS
scans where the five most abundant molecular ions were
dynamically selected and fragmented by collision-induced
dissociation (CID) using a normalized collision energy
of 35% in the LTQ ion trap. Dynamic exclusion was
allowed. Tandem mass spectra were searched against a
suitable protein database using Mascot (Matrix Science)
with the specific enzyme cleavage and variable methionine
oxidation. For higher-energy collisional dissociation
(HCD) measurements, an Orbitrap Fusion Tribrid mass
spectrometer (Thermofisher Scientific) interfaced with an
Easy-nLC 1100 nanoflow liquid chromatography system
(Thermofisher Scientific) was used. In this case, samples
were enriched for phosphoribosylated peptides with Sigma
PHOS-Select iron affinity gel beads (Sigma-Aldrich).
Cell culture, transient transfection and PARP inhibitor
treatment
Human H1299 cells were cultured at 37◦C and 5%
CO2 in DMEM (Gibco), supplemented with 10% fetal
bovine serum (Biochrom), 0.1 u/l penicillin and 0.1
g/l streptomycin (Gibco). K562(HR-EGFP/3’EGFP)
cells were cultivated in RPMI 1640 medium (Gibco)
supplemented with 13% (v/v) fetal bovine serum (Merck
Millipore) and 1.3% (v/v) penicillin–streptomycin–
glutamine (Gibco). Transient transfection of H1299 cells
was performed with Lipofectamine 2000 (Fisher Scientific)
according to the manufacturer’s instruction using 3
l transfection reagent per g DNA. PARP inhibitor
treatment was performed directly afterwards with 10 M
olaparib or veliparib (Selleckchem).
p53 interactome analysis
H1299 cells were transiently transfected with vectors,
encoding Strep-tagged p53 WT, p53 PBM4 or with the
control vector pcdna3.1 using polyethylenimin (PEI).
p53 WT transfected cells were kept in presence or absence
of 10 M olaparib (Selleckchem). As additional control,
non-transfected cells were also used. 24 h later, cells were
lyzed [1% (v/v) NP-40, 10 mM 2-mercaptoethanol, 1 ×
protease inhibitor cocktail with EDTA (Roche), 10 M
olaparib, 50 M gallotannin, in PBS] and treated with 8
g/ml DNase I for 30 min, while rotating at 4◦C. The
lysate was centrifuged and the supernatant was subjected
to a p53 pulldown, by adding 100 l Strep-tactin bead
slurry (IBA, Germany). The samples were incubated for 2 h
while rotating. The samples were centrifuged (from here on
always 2400 g, 20 s), supernatant was removed and beads
were washed three times for 5 min with wash buffer [0.1%
(v/v) NP-40, 10 mM 2-mercaptoethanol, 1 × protease
inhibitor cocktail with EDTA, 10 M olaparib, 50 M
gallotannin, in PBS]. Proteins were eluted from beads by
adding 50 l of a buffer, consisting of 100 mMTris-HCl pH
8.0, 150mMNaCl, 1 mMEDTA and 10mMD-biotin. The
eluted samples were subjected to SDS-PAGE and colloidal
Coomassie staining. Protein bands were excised from the
gel. All samples were reduced with DTT for 30 min at
56◦C and alkylated with chloroacetamide for 60 min at RT.
Digestions were performed using trypsin for 4 h at 37◦C.
Analysis was performed on an Orbitrap Fusion Tribrid
mass spectrometer (Thermofisher Scientific) interfacedwith
an Easy-nLC 1100 nanoflow liquid chromatography system
(Thermofisher Scientific). Samples were reconstituted in
0.1% formic acid and loaded onto the analytical column (75
m× 15 cm) and resolved at a flow rate of 300 nl/min using
a linear gradient of 5−35% solvent B (0.1% formic acid in
acetonitrile) over 45 min. Data-dependent acquisition with
full scans in 350−1500 m/z range was carried out using
the Orbitrap mass analyzer at a mass resolution of 120
000 at 200 m/z. Most intense precursor ions were selected
at top speed data dependent mode with a maximum cycle
time of 3 s. Peptides with charge states 2−5 were selected,
and dynamic exclusion was set to 30 s. Precursor ions
were fragmented using higher-energy collision dissociation
(HCD) set to 35%, and MS/MS ions were detected using
the ion trap analyzer. Tandem mass spectra were searched
against a suitable protein database using Mascot (Matrix
Science) with ‘Trypsin/P’ enzyme cleavage, static cysteine
alkylation by chloroacetamide and variable methionine
oxidation.
Genomic recombination assay
For the determination of the recombination frequency,
K562 cells with stably integrated EGFP-based
recombination substrate were used [K562(HR-
EGFP/3`EGFP)] (37). The principle of this assay is
the restoration of a functional EGFP out of two mutated
EGFP-variants. For investigation of the replication-
associated recombination frequency of K562(HR-
EGFP/3`EGFP) cells and corresponding Western blot
analysis for protein expression, cells were transiently
transfected with pcdna3.1::p53 WT, pcdna3.1::p53 PBM4
expression plasmids or pcdna3.1 empty vector (vector
ctr) via electroporation. Afterwards, cells were exposed
to 2.5 M of PARP-inhibitor olaparib or the solvent
DMSO. After 72 h, cells were collected via centrifugation
and recombination frequency was determined as fraction
of green fluorescent cells within the whole living cell
population by usage of the diagonal gating method in the
FL1/FL2 dot blot (37). Recombination frequencies were
measured by quantification of onemillion cells fromEGFP-
positive cells within the life cell-population (SSC/FSC
gate). Mean values of recombination frequencies of mock-
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treated p53 WT expressing cells were set to 1 (absolute
mean frequency: 7 × 10−6 for mock-treatments).
Luciferase reporter assay
H1299 cells were transfected with DNA vectors encoding
p53 WT or p53 PBM4 together with the Cignal p53
reporter mix (Qiagen). The Cignal p53 reporter mix
contains a plasmid, encoding firefly luciferase, which is
under the control of a minimal CMV promoter and
tandem repeats of p53 transcriptional response elements.
It also contains a plasmid, encoding renilla luciferase,
which is constitutively expressed and used to normalize
for transfection efficiencies and cell viability. 10 M of the
PARP inhibitor olaparib or DMSO as solvent control were
added to the cells. After 24 h, cells were lyzed with theDual-
Glo luciferase reporter assay (Promega), according to the
manufacturer’s instructions. Firefly and renilla luciferase
luminescence were analyzed in technical triplicates using
a Varioscan Flash plate reader (Thermofisher Scientific).
The transactivation activity was expressed as relative
luminescence, which is the ratio of firefly luciferase
luminescence to renilla luciferase luminescence.
Fluorescence recovery after photobleaching (FRAP)
H1299 cells were transfected with DNA vectors,
encoding GFP-tagged p53 WT or p53 PBM4. Bleaching
experiments were conducted 24 h later. To this end,
an LSM880 confocal laser-scanning microscope (Zeiss)
equipped with a 63×/1.4 NA oil-immersion objective
was used. A rectangular region (width: 20 pixels/2.4
m) across the nucleus was bleached using a 488 nm
Argon-ion laser (100% transmission, pixel dwell time:
8.2 s). The fluorescence recovery was followed in a
time series experiment. Before irradiation 20 images were
recorded. Fluorescence intensities within the bleached
region and a non-irradiated nuclear region were measured
for each time point. To compensate photobleaching and
a fast redistribution of unbound proteins during the
bleaching step, for each time point a correction factor was
calculated. After background subtraction, the fluorescence
intensity in the unbleached region was divided by the
average fluorescence intensity measured in the unbleached
region before the bleaching pulse. For each time point, the
background corrected fluorescence intensity was divided by
the respective correction factor. The fluorescence intensity
was then normalized, setting the initial fluorescence
intensity after the bleaching event to ‘0’, and the fully
recovered fluorescence intensity to ‘1’.
p21 protein expression analysis
H1299 cells were transfected with DNA vectors, encoding
p53 WT or p53 PBM4. Cells were lyzed 24 h later with
a buffer consisting of 50 mM Tris-HCl pH 8, 150 mM
NaCl, 1% (v/v) NP40 and protease inhibitor cocktail
(Roche). Protein-content was determined using a BCA
assay kit (Thermofisher Scientific). For expression level
analysis using SDS-PAGE, 30 g or 10 g of total protein
was loaded for detection of p21 or p53, respectively. After
Western blotting, p21was detected using a rabbit polyclonal
p21 antibody (C-19, Santa Cruz).
High-throughput RT qPCR
H1299 cells were transfected with DNA vectors, encoding
GFP-tagged p53 WT or p53 PBM4. Cells were detached
24 h later using trypsin and 10% of the cells were used to
determine transfection efficiency by FACS. The remaining
cells were used for RNA isolation followed by high-
throughput RT qPCRwith Fluidigm dynamic arrays on the
BioMark™ System as described previously (38). To consider
different transfection efficiencies, the Cq calculation of
the respective p53-dependent genes was adjusted according
to Godbey et al. (39).
Statistical information
Unless stated otherwise, Student’s t-test was used to
calculate statistical significance. Significance was defined at
a 5% level and all analyses were performed with GraphPad
Prism 6. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
RESULTS
PAR binds non-covalently to the CTD of p53
To investigate how non-covalent PAR binding affects
p53’s functions, we sought to generate a PAR-binding-
deficient p53 mutant by taking into account the previously
published results by Malanga et al. (22). This study
reported three potential non-covalent PAR-binding sites
within the p53 sequence using synthesized peptides, i.e.,
PBM1–3 (Figure 1A). Using awell-established PARoverlay
assay (40,41), we first verified results by Malanga et al.
showing that peptides of the three PAR binding motifs
(i.e., PBM1–3 WT) efficiently bind PAR. Mutant peptides
derived of PBM1–3 WT comprising exchanges of basic
aa to alanines (i.e., PBM1–3 MUT) showed a strongly
reduced or abolished PAR binding ability (Figure 1B,
peptide sequences in Supplementary Figure S1A). Next,
we generated the corresponding recombinant (rec.) fl-p53
mutants using site-directed mutagenesis. Unexpectedly, an
SDS-PAGE analysis followed by a PAR overlay assay
revealed no reduction in PAR binding of the fl-p53 PBM1–
3 mutants (Figure 1C), indicating that another, so far
unknown, PAR binding site mediates PAR binding of fl-
p53. Using a PepSpot peptide array for screening, we
identified a novel site exhibiting very strong PAR binding
ability in p53’s C-terminal domain (CTD) (peptide 28,
Figure 1D, complete membrane with additional peptides
in Supplementary Figure S1B and C). To verify that the
CTD interacts with PAR, we generated truncated variants
of rec. p53 and tested their PAR binding abilities (Figure
1E and F). In agreement with the PepSpot analysis, the
truncated p53 CTD deletion mutant p53 1–355 completely
lacked PAR binding, revealing that in the context of the fl-
p53 protein, PBMs 1–3 are not relevant for non-covalent
PAR interaction. Instead, our data demonstrates that the
actual relevant PAR binding site in fl-p53 is located in
the CTD, comprising aa 356–393. The mutant p53 1–378,
which comprises half of the CTD, exhibited a significant
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Figure 1. PAR binds non-covalently to the C-terminal domain (CTD) of p53. (A) Schematic representation of the human p53 protein with previously
reported (PBM1–3) and novel (PBM4, aa region 363–382) PAR binding motifs (PBMs). (B) PAR overlay assay after slot-blotting of peptides from PBM1–
3. Basic amino acids (aa) in wildtype (WT) peptides were exchanged to alanines to generate PBMmutants (peptide sequences are shown in Supplementary
Figure S1A). SYPRO Ruby staining served as a loading control. (C) PAR overlay assay after SDS-PAGE of full-length p53 variants with mutated PBMs.
BSA served as a negative control. (D) PAR overlay assay of PepSpot peptide array for the identification of potential PAR binding sites in p53. Ponceau S
staining served as a loading control. Peptide size: 20 aa. The complete membrane with additional peptides is shown in Supplementary Figure S1B and C.
(E) PAR overlay assay after SDS-PAGE of truncated p53 variants. (F) Densitometric quantification of (E). Means ± SEM of 3 independent experiments.
The signal of PAR binding to p53 WT was set to 100%. (G) PAR overlay assay after SDS-PAGE of p53 325–393. BSA served as a negative control.
reduction in PAR binding by 82% compared to fl-p53,
demonstrating that themain PARbinding capacity of p53 is
located at the very C-terminus of aa 379–393. A truncated
p53 mutant consisting of the CTD and the TD (p53 325–
393) confirmed PARbinding of the CTD (Figure 1G). Since
the CTD is highly positively charged (pI = 10.12 for region
356–393), it is plausible that this region can bind to the
highly negatively charged PAR. Since basic aa are essential
for the interaction with PAR, the PAR binding site can
be mapped to aa 363–382. This region resembles the PAR
binding motif (PBM) according to Pleschke et al. (4) and
is identified by in-silico alignment as a PBM when allowing
two aa mismatches (termed ‘PBM4’ from hereon) (Figure
1A). In summary, we have identified the CTD as a novel
PAR interaction site within p53, which accounts for the
majority of the PAR binding ability of fl-p53.
Generation of a PAR-binding-deficient p53 mutant
To generate a PAR-binding-deficient p53 mutant, a
PepSpot array was performed with peptides, in which
critical basic aa were substituted to alanines in two
overlapping regions from the p53 CTD: aa 356–375 and aa
365–384 (Figure 2A, complete membrane with additional
peptides and controls in Supplementary Figure S2A and B).
For the region of aa 356–375, 6 aa exchanges were necessary
to abolish PAR binding, and at least 7 aa exchanges for
the region of aa 365–384. Based on these results, we
incorporated 10 (p53 PBM4–10), 7 (p53 PBM4–7), 5
(p53 PBM4–5) or 4 (p53 PBM4–4) aa exchanges within
the region of aa 363–382 of fl-p53 and tested those mutants
for their PAR binding ability. Since no PAR binding
could be detected in any of those mutants (Figure 2B),
p53 PBM4–4 was used as a PAR-binding-deficient mutant
for subsequent biochemical and functional analyses.
Analytical size-exclusion chromatography (SEC) further
confirmed a highly reduced PAR binding under native
conditions in solution (Supplementary Figure S2C and E).
To investigate if p53 PBM4–4 is still functional, the DNA
binding to a p53 response element from the p21 promoter
(REp21) was analyzed by an electrophoretic mobility shift
assay (EMSA) (Figure 2C and D) and by analytical SEC
(Supplementary Figure S2D and E). Under the tested
conditions, the DNA binding affinity of the p53 PBM4–4
mutant was not significantly altered compared to p53 WT.
Furthermore, cellular chromatin binding was comparable
between p53 WT and p53 PBM4–4 (Supplementary Figure
S2F-H). Fluorescence recovery after photobleaching
(FRAP), which is a measure for chromatin binding,
further revealed that the cellular mobilities of p53 WT and
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Figure 2. Generation of a PAR-binding-deficient p53 mutant. (A) PAR overlay assay of PepSpot peptide array of CTD mutants with 1–9 aa exchanges.
Ponceau S staining served as a loading control. Peptide size: 20 aa. Amino acids highlighted in blue were subjected to exchanges to alanines. The complete
membrane with additional peptides and controls is shown in Supplementary Figure S2A and B. (B) PAR overlay assay after SDS-PAGE of full-length p53
with mutated PBM4. Exchanges of 10, 7, 5 or 4 aa were introduced into the CTD, which is shown in the table below. Basic aa (in blue) were subjected to
exchanges to alanines (in red). (C) Electrophoretic mobility shift assay (EMSA) with p53 WT and p53 PBM4–4, binding to the fluorescently labeled DNA
substrate REp21. (D) Densitometric quantification of (C). (E) FRAP analysis in H1299 cells reconstituted with GFP-tagged p53 WT or p53 PBM4–4.
Recovery of GFP was measured after photobleaching. Means ± SD of six cells. (F) Analytical size-exclusion chromatography with p53 WT, p53 1–355,
p53 PBM4–4 and a tetramerization-deficient p53 mutant (p53 L344P). Size-calculations are shown in Supplementary Figure S2E.
p53 PBM4–4 are very similar (Figure 2E). Additionally,
the tetramerization of p53 PBM4–4 is not adversely
affected by the aa exchanges (Figure 2F). In summary, we
successfully generated a p53 mutant with strongly reduced
PAR binding by exchanging four basic aa within the CTD,
again verifying that aa 363–382 of p53 are of critical
importance for the non-covalent p53–PAR interaction.
Influence of non-covalent PAR binding on biochemical
properties of p53
The DBD of p53 is known to bind in a sequence-
specific manner to p53 response elements, whereas DNA
binding abilities of the CTD are thought to be more
versatile and sequence-independent (42). As previously
reported, non-covalent PAR binding to p53 inhibits p53’s
DNA binding ability (22). As these experiments did
not distinguish between DBD and CTD-mediated DNA
binding, we investigated how non-covalent PAR binding
influences the separate DNA-binding abilities of the DBD
and the CTD using an in-vitro DNA-PAR competition
EMSA. Both p53 fragments, i.e., p53 1–355 and p53 325–
393, bound to the fluorescently labeled DNA substrate
REp21. However, while DNA binding by p53 325–393
(i.e., comprising the CTD) was highly impaired by PAR
and entirely suppressed at higher PAR concentrations,
the DNA binding of p53 1–355 (i.e., comprising the
DBD) was only mildly influenced (Figure 3A and B).
To discriminate between sequence-specific and sequence-
independent DNA binding of p53, we compared its DNA
binding ability to REp21 or a scrambled version thereof
(i.e., scrambled REp21) in the absence or presence of
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Figure 3. Influence of non-covalent PAR binding on biochemical properties of p53. (A) DNA-PAR competition EMSA. DNA binding of p53 1–355 (1.5
M) or p53 325–393 (18.7 M) to a fluorescently labeled DNA substrate REp21 was competed with non-fractionated, unlabeled PAR. Note that DNA
binding via p53 1–355 comprising the sequence-specific DBD results in formation of discrete complexes detectable as single bands, whereas p53 325–
393 comprising the sequence-independent DNA binding CTD results in formation of heterogeneous complexes detectable as smears. (B) Densitometric
quantification of (A). Means ± SEM of >3 independent experiments. Statistical significance was analyzed via two-way ANOVA. (C) Differential scanning
fluorimetry (DSF) analysis with p53. Influence of PAR and DNA on the melting temperature of p53 was analyzed. Means ± SEM of 3 independent
experiments. Only relevant significances are depicted. (D) Analysis of p53–PARP1 interaction in vitro by coIP. Recombinant (rec.) PARP1was immobilized
on beads and subjected to an auto-PARylation reaction. Rec. p53 was added and the interaction with PARP1 was analyzed using appropriate antibodies.
(E) Densitometric quantification of (D). Means ± SEM of three independent experiments.
PAR (Supplementary Figure S3). PAR equally efficient
outcompeted the binding of p53 325–393 to scrambled
REp21 and REp21, reflecting the sequence-independent
DNA binding nature of the CTD. Consistent with the
finding that the CTD is the center of PAR-dependent
regulation, PAR outcompeted the interaction of p53 WT
with scrambled REp21 more efficiently as compared to
REp21. p53 PBM4–4 showed an intermediate competition
behavior between p53 WT and p53 1–355. In summary,
these results demonstrate that PAR directly inhibits CTD-
mediated sequence-independent DNA binding of p53,
however, CTD-bound PAR chains can also alter the DBD-
mediated DNA binding in fl-p53.
Previously, it was shown by differential scanning
calorimetry that the addition of a p53 response element
to the core domain of p53 leads to an increase in
its melting temperature (Tm) (43). To test how PAR
affects the thermodynamic stability of p53, differential
scanning fluorimetry (DSF) was performed (Figure 3C).
Indeed, the presence of PAR resulted in an increase
of Tm. Furthermore, this increase was PAR chain length
dependent beingmore pronouncedwith longer PAR chains.
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This is consistent with previous findings showing increased
affinity of longer PAR chains to p53 (21). However, the
stabilizing effect of PAR was much weaker than of the
DNA substrate REp21, suggesting that the interaction
works by different binding mechanisms, potentially by
electrostatic interactions. The DNA-PAR competition
revealed that longer PAR chains can compete more
efficiently with the DNA-p53 binding than short PAR,
again being in line with the higher affinity of p53 to long
PAR chains. Neither the melting temperature of p53 1–355
alone nor in combination with REp21 was influenced by
PAR verifying that PAR binding is mediated by the CTD of
p53. Consistent with this notion, the melting temperature
of p53 PBM4–4 was not influenced by the presence of PAR
itself. However, the increase in Tm mediated by the addition
of REp21 could be partly inhibited by addition of PAR,
indicating that p53 PBM4–4 still exhibits some residual
PAR-binding under certain conditions.
Since in cells it is thought that the majority of PAR
molecules are covalently attached to PARP1, we performed
in-vitro co-immunoprecipitation (coIP) experiments with
auto-PARylated or unmodified PARP1 to investigate how
auto-PARylation of PARP1 influences the p53–PARP1
interaction (Figure 3D and E). To this end, rec. PARP1
was immobilized via a PARP1-specific antibody on protein
G -coated beads, followed by auto-PARylation, high-
stringency washing, and finally co-incubation with rec.
p53 variants. About 10-fold more p53 was bound to
auto-PARylated PARP1 compared to unmodified PARP1.
Consistent with the notion that PAR mediates the p53–
PARP1 interaction, the interaction of auto-PARylated
PARP1 to p53 PBM4-4 was highly reduced and the
interaction to p53 1–355 was almost completely abolished.
This reveals that auto-PARylation of PARP1 represents
a prerequisite for the efficient interaction with p53
and that PAR functions as a bridge for the p53–
PARP1 interaction. The results from Figure 3C–E and
Supplementary Figures S2C and S3D suggest that under
certain conditions native, tetramerized p53 PBM4–4 is not
entirely deficient in PAR-binding, since tetramerization
can potentially compensate for the removal of basic aa.
Thus, in conclusion, our data indicate that p53 PBM4–
4 represents a compromise between reduced PAR binding
and still maintained biochemical functionality, e.g., in terms
of DNA binding. Keeping this in mind, we used the
p53 PBM4–4mutant in combinationwith pharmacological
PARP inhibition to functionally analyze consequences of
non-covalent p53–PAR interaction on a biochemical as
well as on a cellular level. In summary, these results show
that (i) PAR binding inhibits CTD-mediated sequence-
independent DNA binding of p53, (ii) the p53–PAR
complex is of lower thermodynamic stability than the p53–
DNA complex, despite its high binding affinity, and (iii) the
p53–PARP1 interaction can be strongly induced by auto-
PARylation of PARP1.
The CTD of p53 is essential for covalent PARylation of p53
To investigate a potential influence of the CTD on the
covalent PARylation of p53, truncated p53 variants were
tested for their ability to be covalently PARylated using
an in-vitro PARylation assay. In this assay, covalent
PARylation was tested by mixing rec. p53 variants with
rec. PARP1 in the presence of NAD+. Due to covalent
PARylation of rec. proteins with different sizes of PAR,
the signals in the subsequent Western blot appeared as a
diffuse band (‘smear’), by which it can be determined, if a
protein is covalently PARylated or not. Strikingly, covalent
PARylation was completely abolished in the p53 1–
355 variant (Figure 4A), indicating that non-covalent
interaction of PAR with the CTD is also essential for the
covalent PARylation of p53. Consistently, p53 1–378, which
had shown residual non-covalent PAR binding (Figure 1E),
exhibited covalent PARylation. To analyze if the CTD is
a target for covalent PARylation itself, or if it mediates
the interaction to PARP1, we developed a thrombin
cleavage assay. To this end, a thrombin cleavage site (TCS)
was introduced between aa 324 and 325 (p53 324-TCS-
325, Figure 4B), which separates the DBD from the
TD. When a PARylation reaction was performed with
the p53 324-TCS-325 variant, followed by the thrombin
cleavage, a ∼10-kDa down-shift of the PARylated band
indicated that the covalent PARylation signal remained at
the larger p53 1–324 fragment (Figure 4C, lanes 3 and
4). This demonstrates that covalent PARylation occurs
mainly within the region of aa 1–324 of p53. No additional
PARylated band was detected at lower molecular weights.
To exclude that thrombin itself caused PAR degradation,
thrombin was added to PARylated p53 WT lacking a
TCS. In this case, no down-shift was observed (Figure
4C, lanes 1 and 2). Previously, covalent PARylation sites
were mapped to sites E255, D256 and E268 of murine p53
(23). We exchanged the corresponding aa in human p53
to alanines, but covalent PARylation still occurred (lane
‘p53 EDE/A’ Supplementary Figure S4A). Thus, to map
the exact location of covalent PARylation in human p53,
we performed high-resolution Orbitrap mass spectrometry
(MS) according toDaniels et al. (33). Covalently PARylated
p53 was treated with phosphodiesterase I (PDE I) to
reduce the PAR chain length, resulting in one remaining
protein-bound phosphoribose moiety. Efficient PDE I
treatment was controlled by Western blotting for PAR
(Supplementary Figure S4B). Using this procedure, we
identified several covalent PARylation sites in the TAD of
p53 (Figure 4D). Thus, after trypsin digestion, aa E2, D7
or E17 were identified as highly likely targets for covalent
PARylation. After pepsin digestion, aa E28 was identified
as a covalent PARylation site (Figure 4D, Supplementary
Figure S5). We next sought to generate a p53 mutant
deficient or impaired for covalent PARylation. To this
end, aa E28 alone or in combination with aa E2, D7,
E17 or other potential PARylation sites were exchanged
to alanines. An in-vitro PARylation assay revealed that
covalent PARylation still occurred in these rec. p53mutants.
No decrease in band intensities was observed (Figure 4E).
To test if covalent PARylation occurs C-terminally of
E28 or outside of the TAD, a TCS was introduced into
the p53 sequence between aa 28 and 29 (p53 28-TCS-29)
or between aa 68 and 69 (p53 68-TCS-69), respectively.
Thrombin cleavage of covalently PARylated p53 28-TCS-
29 or p53 68-TCS-69 resulted in a ∼10 or ∼15-kDa
down-shift, respectively, of the PARylated bands (Figure
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Figure 4. The CTD of p53 is essential for covalent PARylation of p53. (A) In-vitro PARylation assay to test covalent PARylation of C-terminally truncated
versions of p53. (B) Schematic representation of the here used human p53 protein variants containing a thrombin cleavage site (TCS). (C) Thrombin
cleavage assay with covalently PARylated p53 324-TCS-325. Down-shifted bands are indicated by red brackets, bands of non-thrombin-treated samples
by blue brackets. (D) Mass spectrometric identification of covalent PARylation sites in p53 WT. PDE I –treated PARylated p53 was trypsin or pepsin
digested. (E) In-vitro PARylation assay with p53 containing mutations at the PARylation sites identified in (D). PARP1: A control PARylation reaction
was performed in the absence of p53 variants. (F) Thrombin cleavage assay with covalently PARylated p53 28-TCS-29 or p53 68-TCS-69. (G) In-vitro
PARylation assay with N-terminally truncated versions of p53. (H) In-vitro PARylation assay with p53-PBM4 mutants. Exchanges of 10, 7, 5 or 4 aa were
introduced into the CTD (protein sequences are shown in Figure 2B).
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4F), demonstrating that covalent PARylation occurs C-
terminally of E28 and C-terminally of the TAD. (N.B.
The actual downshift differs slightly from the theoretically
calculated one, because of high proline content and
additional PARylation of the N-terminus.) We cannot
rule out that PARP1 has preferential target sites for
covalent PARylation in p53, but our experiments provide
substantial evidence that PARP1 modifies various target
sites throughout the whole p53 protein with rather broad
specificity. To investigate if PARP1 covalently PARylates
p53 variants with partial or full deletion of the TAD, we
generated N-terminally truncated p53 variants. An in-vitro
PARylation assay demonstrated that p53 29–393, as well as
p53 69–393 can still be covalently PARylated. Intriguingly,
even the p53 325–393 variant can be covalently PARylated,
although to a lesser extent (Figure 4G). This suggests
that the only denominator that is essential for covalent
PARylation of p53 is the CTD and that the selection of the
modification site by PARP1 is rather promiscuous.
To examine if non-covalent PAR binding to the CTD is
a prerequisite for covalent PARylation, the PAR binding
mutants p53 PBM4–10, p53 PBM4–7, p53 PBM4–5 and
p53 PBM4–4 were tested for covalent PARylation. Indeed,
all of them were deficient for covalent PARylation (Figure
4H), indicating that non-covalent PAR binding of the
CTD is necessary for covalent PARylation of p53. Thus,
p53 PBM4–4 can be employed as a mutant deficient for
both non-covalent as well as covalent PARylation (termed
‘p53 PBM4’ from hereon).
To exclude potential antibody artifacts in the
PARylation-deficient mutants or truncations, the in-
vitro PARylation assay was performed with radioactive
32P-NAD+ (Supplementary Figure S4C). Consistent with
immunochemical results, a subsequent autoradiographic
detection showed that p53 PBM4 and p53 1–355 were
deficient for covalent PARylation. Additionally, to ensure
that only covalent PARylation of p53 is detected in
our SDS-PAGE analysis without residual non-covalent
PAR–p53 interaction, we added the chaotropic agent
urea in a concentration of 8 M to samples after the
PARylation reaction, followed by incubation at 95◦C for
5 min (Supplementary Figure S4D). No reduction in the
PAR signal was observed, verifying that PAR is covalently
attached to p53. Furthermore, a PARP inhibitor was added
to auto-PARylated PARP1, followed by addition of rec.
p53. The absence of a PARylated p53 signal indicated
that p53 did not show residual PAR binding, despite the
presence of PAR from the auto-modification of PARP1
(Supplementary Figure S4E). Also, when purified PARwas
co-incubated with rec. p53, no PAR signals were detected
after SDS-PAGE analysis (data not shown).
In summary, these results provide strong evidence that
non-covalent PAR binding to the CTD mediates the
interaction of p53 with auto-PARylated PARP1, thereby
triggering the covalent PARylation of p53. Further, p53 is
covalently PARylated throughout the whole protein raising
the possibility that PARP1 selects the modification site with
rather broad specificity.
Fusing the CTD of p53 to GST renders GST a target for
covalent PARylation
Since the interaction of the CTD with auto-PARylated
PARP1 appears to be the key factor for targeting p53
for covalent PARylation, we tested if fusing the CTD to
a protein that is normally not a substrate for covalent
PARylation renders this a target for PARylation. To this
end, we chose glutathione S-transferase (GST), which is
a widely used negative control for covalent PARylation
(44–46). The CTD alone (aa 359–387) or the TD-CTD
(aa 325–393) were fused to the C-terminus of GST,
separated by a TCS (i.e., GST-p53 359–387 and GST-
p53 325–393, respectively). Interestingly, those two fusion
proteins were indeed covalently PARylated in an in-vitro
PARylation assay, in contrast to GST alone (Figure 5A).
Since covalent PARylation potentially can also take place
directly within the TD or CTD, we performed a thrombin
cleavage assay with PARylated GST-p53 359–387 or GST-
p53 325–393. In the case of GST-p53 325–393, a ∼10-
kDa down-shift of the PARylated band demonstrated that
covalent PARylation mainly occurred indeed within the
GST sequence (Figure 5B). To observe the low molecular
weight down-shift after thrombin cleavage of PARylated
GST-p53 359–387 with suitable sensitivity, we switched
to the use of the anti-PAR antibody LP96–10, which
recognizes shorter PAR chains than the 10H antibody,
thus enabling detection of the PARylation signal in the
lower molecular weight range. A ∼4-kDa down-shift of
the PARylated protein band after thrombin cleavage clearly
demonstrated that covalent PARylation occurred within
the GST sequence (Figure 5C). Of note, in cells, GFP,
which is usually not covalently PARylated, is targeted for
covalent PARylation if it is fused to the extendedC-terminal
region of p53 (aa 301–393). (Supplementary Figure S4F).
In summary, these results demonstrate that fusing the CTD
of p53 to a peptide sequence that is usually not PARylated
renders it a target for covalent PARylation.
Covalently PARylated proteins are highly enriched in CTD-
like regions
Since the CTD targets a protein for covalent PARylation,
the question arises if other PARylated proteins also contain
regions that resemble p53’s CTD with regards to positive
charge density and degree of structural disorder. To identify
such regions, we performed a bioinformatics analysis using
mass spectrometry data sets for covalently PARylated
proteins under genotoxic conditions published by Zhang
et al. (27), Jungmichel et al. (26), and Martello et al.
(25). First, intrinsically disordered protein regions (IDPRs)
were predicted in the PARylated proteins, using the IUpred
algorithm (28,29). Next, these IDPRs were screened for
presence of highly positively charged regions. Since p53 1–
378 and GST-p53 359–387 showed covalent PARylation
and a net aa charge of at least +4, this ≥ +4 net charge was
chosen as an in-silico search pattern in a sliding window of
a total of 15 aa. To calculate the net charge, the amount
of the basic aa arginine or lysine was subtracted by the
amount of the acidic aa glutamate or aspartate. If a directly
consecutive region was identified, it was merged with the
previous region. This procedure demonstrated that 68%
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Figure 5. Fusing the CTD of p53 to GST renders GST a target for covalent PARylation. (A) In-vitro PARylation assay with 97 pmol GST, GST-p53 325–
393 or GST-p53 359–387. In comparison, covalent PARylation of 5 pmol p53 WT is shown. (B) Thrombin cleavage assay with covalently PARylated
GST-p53 325–393. Down-shifted bands are indicated by red brackets, bands of non-thrombin-treated samples by blue brackets. (C) Thrombin cleavage
assay with covalently PARylated GST-p53 359–387.
of the PARylated proteins from Jungmichel et al., 86%
from Martello et al. and 84% from Zhang et al. contain
highly basic IDPRs (Figure 6A and B, details of identified
proteins and sequences in Supplementary Data 1). In
comparison, the whole human proteome contains 38% of
proteins with highly basic IDPRs. Since PARP1 is mainly
active in the nucleus, cytoplasm-localized proteins from the
eSLDB database were used as an additional control pool
in the analysis (30). 39% of these proteins contain highly
basic IDPRs. The proteome of N-glycosylated proteins
was used as a non-PARylation-associated control pool,
as employed recently also in other studies (20,31). This
dataset exhibits only 20% of proteins that contain highly
basic IDPRs. These results demonstrate that covalently
PARylated proteins are markedly enriched in highly basic
IDPRs. Frequently, the PARylated proteins showed very
long highly basic IDPRs, with lengths of 40–50 aa and
even longer. The highly basic IDPR of p53 is only 24
aa in length, but tetramerization can markedly increase
the charge density. To investigate if tetramerization of p53
influences covalent PARylation, we performed the in-vitro
PARylation assay in the presence of the tetramerization-
deficientmutant p53 L344P (47). PARylation of p53 L344P
still occurred, although to a lesser extent than with
p53 WT (Supplementary Figure S4A), indicating that
tetramerization is not strictly essential, however supports
covalent PARylation of p53. To test if similar regulatory
mechanisms of non-covalent PAR binding and covalent
PARylation exist in proteins other than p53, we analyzed
this crosstalk for the DEK protein, which was previously
identified as a non-covalent PAR binding protein and a
substrate for covalent PARylation (25,26,48). In a recent
study, the strongest non-covalent PAR interaction was
mapped to aa positions 195–222 (Ganz, Vogel et al.,
manuscript in preparation). This region was also identified
as a highly basic IDPR by our algorithm (i.e., aa 177–
227; a second IDPR was identified in the region aa 254–
292). Within the PAR binding region of aa 195–222, nine
basic aa were exchanged to alanines followed by expression
and purification of the recombinant protein. Consistent
with results from p53, this mutant showed a reduced non-
covalent PAR binding (Figure 6C and D) and covalent
PARylation (Figure 6E). To investigate if binding of PAR to
other types of PAR binding modules also controls covalent
PARylation, we used the in-vitro PARylation assay in the
presence of the macrodomain protein Af1521, which lacks
highly basic IDPRs (PDB entry 1VHU). The macrodomain
binds to PAR non-covalently specifically via the terminal
ADP-ribose moiety (49). In this case, we did not detect
covalent PARylation of Af1521 in vitro (Supplementary
Figure S4A and C), suggesting that not all modes of
non-covalent PAR binding render a protein a target for
covalent PARylation by PARP1. In summary, these results
demonstrate that CTD-like regions are present in most
other covalently PARylated proteins, supporting the notion
that such highly basic IDPRs may target such proteins for
covalent PARylation as well.
Influence of PAR on cellular functions of p53
To investigate if and how PAR affects cellular functions
of p53, pharmacological PARP inhibition and/or the
p53 PBM4 mutant were employed to analyze (i) the
transactivation activity of p53, (ii) p53-dependent
replication-associated recombination and (iii) the PAR-
mediated p53 interactome. To this end, p53-deficient
human cells were reconstituted with p53 WT or p53 PBM4
by transfection and treated with the PARP inhibitor
(PARPi) olaparib or left untreated. Since the transfection
procedure itself produces considerable amount of genotoxic
stress (50,51) and high levels of p53, we analyzed cellular
effects without inducing DNA damage using additional
genotoxins. By using protein purification of His-tagged
p53 from transfected cells, we confirmed that under those
experimental conditions covalent PARylation of p53 occurs
in cells (Supplementary Figure S6).
The transactivation activity was determined by a
luciferase reporter assay, using a firefly luciferase gene
driven by tandem repeats of p53 response elements.
Notably, p53 PBM4 showed a significant 37%-reduction
in relative luminescence compared to p53 WT (Figure
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Figure 6. CTD-like regions are present in the majority of covalently PARylated proteins. (A) Schematic representation of the bioinformatics analysis to
search for CTD-like regions in PARylated proteins. Protein sequences from data sets of covalently PARylated proteins (25–27) were retrieved and analyzed
for presence of predicted intrinsically disordered protein regions (IDPRs). In a next step, screening for highly basic IDPRs was performed, which represent
CTD-like regions. (B) Bioinformatics analysis for the identification of CTD-like regions in covalently PARylated proteins. Data from cultured cells under
genotoxic stress conditions used from Zhang et al. (27), Jungmichel et al. (26) and Martello et al. (25). P < 0.0001 for any pairwise comparison between a
PARylated protein dataset and a control protein dataset; chi-square test. (C) PAR overlay assay after SDS-PAGE of full-length GST-tagged DEKwith 9 aa
substitutions (GST-DEK PBM) in a highly basic IDPR PAR binding motif. (D) Densitometric quantification of (C). Means ± SEM of three independent
experiments. The signal of PAR binding to DEK WT was set to 100%. (E) In-vitro PARylation assay with DEKmutant from (D) using anti-PAR anibody
LP96–10.
7A). PARPi treatment in p53 WT-transfected cells reduced
the relative luminescence also significantly by 19%, while
PARPi in p53 PBM4-transfected cells did not change the
relative luminescence, indicating an epistatic effect. To
examine the influence of PARylation on gene expression in
a chromatin environment, we analyzedCDKN1A (encoding
for p21) mRNA transcript levels and p21 protein levels
(Figure 7B–D). These results demonstrated that PAR
enhances the transactivation activity of p53 also in an
endogenous chromosomal encoded gene. mRNA levels of
the p53-dependent target genes SLC30A1 and RRM2B
showed comparable results (Supplementary Figure S7).
MDM2 mRNA levels exhibited a dependence on olaparib,
whereas PLK3 showed a p53 PBM4-dependent effect.
These results indicate that aa exchanges in PBM4 can also
result in PAR independent effects, which is not surprising
considering the broad modification of the CTD by other
post-translational modifications and its versatile role in the
regulation of many p53 functions. Other potential p53-
dependent target genes from a previously published gene
set (38) showed no dependence on PARP inhibition or
p53 PBM4.
A previous report demonstrated that two NLS sequences
of low activity are located in the CTD (52). To exclude
that the transactivation function is influenced due to altered
subcellular localization of p53, high-content fluorescence
microscopy with GFP-tagged p53 variants was performed.
The ratio of nuclear to cytoplasmic p53-GFP intensity was
not significantly different for p53 WT (with or without
PARPi) or for p53 PBM4 (Supplementary Figure S8),
indicating that PARPi treatment and the aa exchanges in
the CTD of the p53 PBM4 mutant did not influence p53’s
nuclear localization in the experimental system used in this
study.
Since p53 stimulates replication-associated
recombination, which is assumed to protect replicating
DNA (53), we analyzed recombination using a
chromosomally integrated recombination reporter
substrate (Supplementary Figure S9A) (37,54). Notably,
p53 PBM4 showed a significantly reduced stimulation
of the recombination rate compared to p53 WT (Figure
7E and Supplementary Figure S9B). Furthermore,
p53 WT in presence of PARPi displayed a complete
loss of recombination stimulation. These results suggest
that PAR is of critical importance for the p53-mediated
recombination stimulation, however, additional PAR-
dependent factors, which are not directly related to
the non-covalent p53–PAR interaction, appear to be
also involved in the regulation of replication-associated
recombination.
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Figure 7. Influence of PAR on cellular functions of p53. (A): Analysis of p53 transcriptional activity using a luciferase reporter assay. H1299 cells were
transfected with p53 WT or p53 PBM4, ± PARP inhibitor. Relative luminescence: Ratio of firefly to renilla luciferase luminescence. Renilla luciferase
luminescence was used for the normalization of transfection efficiency. Means ± SEM of six independent experiments. (B) p21 protein expression level of
experimental system in (A). Actin served as loading control. (C) Densitometric quantification of (B). Means ± SEM of 3 independent experiments. p21
levels were normalized to p53 levels and p53 WT without olaparib was set to 100%. (D) CDKN1A gene expression of experimental system in (A) using
RT-qPCR.Means± half range of 2 independent experiments. (E) Determination of relative replication-associated recombination frequencies of K562(HR-
EGFP/3`EGFP) cells, transfected with p53 WT or p53 PBM4, ± PARPi. Means ± SEM of 12 independent measurements. Statistical significance was
analyzed via two-tailed Mann–Whitney U test. (F) Schematic representation of the proteomics experiment to identify PAR-mediated interaction partners
of p53. H1299 cells were reconstituted with p53 WT ± PARPi or p53 PBM4, followed by pulldown of p53 complexes and MS analysis. (G) Identified
PAR-mediated interaction partners of p53 by the proteomics experiment described in F. (H) Mechanistic model of targeting p53 for covalent PARylation
by PARP1. PARP1 is activated upon DNA single-strand break detection and subsequently auto-PARylates itself. p53 binds via the CTD non-covalently
to PAR chains from auto-PARylated PARP1 and is put into spatial proximity of the catalytic center of PARP1, followed by covalent PARylation of p53 by
PARP1. In consequence, the spatio-temporal function of p53 are affected, such as DNA binding properties, transcriptional function, replication-associated
recombination and specific protein-protein interactions.
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To identify PAR-mediated p53 interaction partners, a
p53 pulldown combined with a proteomics analysis was
performed, using a high-stringency approach. Thus, an
interaction of p53 with another protein was considered
to be PAR-mediated, if at least a 4-fold difference in
abundance was present between p53 WT and p53 PBM4,
as well as between p53 WT and p53 WT treated with
PARPi. The fact that PARP1 was identified as a PAR-
mediated interaction partner confirms our above coIP
results in a cellular environment. Furthermore, Annexin
A1, 40S ribosomal protein S8, zinc-alpha-2-glycoprotein,
histone H4 and histone H3 variants were identified as
PAR-mediated interaction partners (Figure 7F and G
and Supplementary Data 2, Supplementary Figure S9C).
With the exception of zinc-alpha-2-glycoprotein, all of
these proteins were previously identified as PAR binding
factors (55). Our results now show that these PAR-protein
interactions bridge the interaction with p53 in the cell,
thereby demonstrating that the interactome of a given
protein, i.e., p53, is directly PAR dependent.
In summary, these results demonstrate that PAR acts as
a significant regulator of p53 cellular functions regarding
transactivation function, p53-mediated replication-
associated recombination, and p53 protein interactions.
DISCUSSION
This study reveals that the previously reported high-
affinity interaction of PAR with p53 is mediated by
its CTD. The non-covalent PAR binding mediates the
interaction of p53 with auto-PARylated PARP1, which
then targets p53 for covalent PARylation. In consequence,
PARylation regulates several essential cellular functions
of p53, such as its transcriptional activity, replication-
associated recombination, and specific protein interactions,
revealing the CTD as the center for regulation of p53 by
PARylation (Figure 7H). By this, the current study gives a
prime example of how the two modes of PARmodification,
i.e., non-covalent PAR binding and covalent PARylation,
crosstalk in case of one of the most important tumor
suppressor proteins, i.e., p53, with significant functional
consequences on the cellular level.
The CTD plays a multifunctional role in nearly every
aspect of p53 regulation, such as protein stability,
recruitment of co-factors, and the complex binding
behavior of p53 to DNA (8). Apart from its sequence-
independent interaction with double-stranded DNA,
various other DNA structures act as CTD binding
partners, such as single-stranded DNA, insertion/deletion
mismatches, recombination intermediates, as well as DNA
single-strand and double-strand breaks. Additionally,
interaction with RNA was demonstrated (8,56,57). Due
to this variety of different binding partners, which are
based on electrostatic interactions, the CTD was previously
suggested to be a sequence-independent DNA binding
domain (42). The different functions of the CTD are
regulated by a host of post-translational modifications,
such as phosphorylation, ubiquitination, methylation, and
acetylation. While a role of PARylation was previously
proposed in the regulation of p53 (22,23), its molecular
details and functional significance are only poorly
understood. Thus, Malanga et al. suggested that non-
covalent p53–PAR interaction may take place in p53’s
DBD and TD (i.e., PBMs 1–3) (22). We reproduced these
results, which were based on peptide studies. However,
interestingly PBMs 1–3 were of no or only minor relevance
for PAR binding in fl-p53, potentially because these
binding sites are not accessible in the full-length protein.
Instead, we revealed that the actual PAR binding ability
resides in the CTD of p53. The reason of why Malanga et
al. did not identify the CTD as a PAR binding region may
be attributed to the fact that in some cases peptides are not
efficiently bound to the membrane during the PAR overlay
assay, because of solubility issues.
Due to the similar chemical characteristics compared to
DNA and RNA, a high-affinity electrostatic interaction
of PAR with the CTD is plausible. The ability to interact
with different types of nucleic acids, i.e., DNA, RNA,
PAR, may be necessary to regulate the binding of p53
to the different nucleic acid targets and thereby control
its specific cellular functions. Given that PAR contains
two negatively charged phosphate groups per ADP-ribose
moiety, the charge density and thus the affinity is probably
at least as high as for RNA or DNA. Since upon DNA
damage, cellular PAR levels can rise >100-fold (58) and the
local PAR content at the DNA damage site can reach high
peak values, PAR potentially has the ability to outcompete
DNA and RNA binding (59). In this way, PAR may serve
as an important and highly dynamic factor to regulate
the binding of p53 to other nucleic acids in a spatio-
temporal manner. We demonstrated that PAR inhibited
mainly the sequence-independent, CTD-mediated DNA
binding of p53. In contrast, the sequence-specific DNA
binding via the DBD was only moderately affected. It was
previously demonstrated that p53 binds to a high degree
at non-specific DNA target sites in cells. Only about 2–
5% of p53-bound DNA target sites have a p53 consensus
motif (60,61). Thus, non-covalent PAR binding to the CTD
could possibly decrease the sequence-independent DNA
binding by competition, leading to an increased specific
DNA binding after PAR formation.
Intriguingly, our results show that the PAR-binding
CTD is also essential for covalent PARylation of p53.
Together with the finding that p53 binds more efficiently
to auto-PARylated than unmodified PARP1, this strongly
indicates that non-covalent p53–PAR interaction provides
the target specificity for its covalent PARylation by
PARP1 (Figure 7H). In general, the connection between
non-covalent PAR binding and covalent PARylation is
understood incompletely. Previous work showed that the
PARP1 interaction to many proteins, such as CHD2 (62)
or DNMT1 (63) is PAR-mediated. This indicates that
the covalent PARylation of these proteins by PARP1
may be PAR-mediated, as well. This is supported by the
identification of CHD2 as a target for covalent PARylation
(27). Consistently, many PAR-binding proteins are also
targeted by covalent PARylation (3). In support of this
notion, we showed that in addition to p53, covalent
PARylation of DEK is dependent on non-covalent PAR-
DEK interaction (Figure 6C–E). We propose that a
combination of intrinsic disorder and high positive charge
confers non-covalent PAR binding and subsequently leads
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to PARP1-mediated covalent PARylation of p53, DEK,
and potentially other proteins. For example, the proteins
FUS, EWS and TAF15, which bind non-covalently to PAR
by their long, intrinsically disordered and highly positively
charged RGG repeats (64), are also a target for covalent
PARylation (26). The same was demonstrated for the short
N-terminal tails from histones, which also comprise highly
basic IDPRs (44). On the contrary, covalent PARylation
was not detected in case of the PAR-binding macrodomain
(this and previous studies (26)). A possible explanation
can be that IDPRs provide the ability to slide along the
PAR chain towards PARP1 to reach spatial proximity for
covalent PARylation, which is supported by studies showing
that IDPRs slide along DNA in a sequence-independent
manner (13,14,65). In contrast, the macrodomain binds to
the terminal ADP-ribose moiety of the PAR chain by a
specific fold and is probably too distant from the catalytic
center of auto-PARylated PARP1 for covalent PARylation.
Recently, thousands of covalently PARylated proteins were
identified by mass spectrometry. Interestingly, the majority
of these proteins have regions that are similar to the CTD
of p53 in the way that they are also highly basic and
disordered. These regions could account for non-covalent
PAR binding and for covalent PARylation of proteins,
offering a possible explanation of how PARP1 can select
its thousands of targets for covalent PARylation.
In general, protein kinases recognize their target sites for
phosphorylation at a specific aa consensus sequence (66). In
comparison, our results strongly suggest that PARP1 does
not require a certain aa consensus sequence for the selection
of covalent PARylation sites. Instead, PARP1 targets a
protein, if it exhibits a PAR interaction domain like the
CTD and suitable acceptor aa. The high variety of different
acceptor aa, such as glutamate, aspartate, lysine and serine
supports this notion (2,33). Furthermore, PARP1 can
even covalently modify DNA strand break termini in
DNA fragments, at least in vitro (67). In consequence,
the selectivity of PARP1 towards specific aa substrates is
under current discussion in the field (3,68). In principle,
such a broad specificity might be necessary to render the
response upon certain PARP1-activating stimuli as wide
and adaptive as possible. Importantly, however, in a cellular
context, PARP1 specificity could be regulated by additional
co-factors, as was recently demonstrated for HPF1, which
is necessary for serine-specific PARylation (2).
This study demonstrates that PARylation participates
in the transactivation function of p53 in cells, which
is consistent with previous studies (17,69). Additionally,
we show that this regulation is dependent on PBM4. A
possible mechanism may be that p53 needs to dissociate
from DNA for the start of transcription, which may be
mediated by PARylation of p53. Treating cells with a PARPi
prevents the dissociation of p53 and TAFs (TATA binding
protein associated factors) from the p21 promotor (70). Our
data implicate that covalent PARylation of p53 can also
occur with DNA-bound p53, since DBD-mediated DNA
binding was only moderately influenced by the presence
of PAR. Therefore, auto-PARylated PARP1 can bind to
p53, followed by covalent PARylation and dissociation
of p53 from the DNA. Moreover, PARylated p53 might
enhance the recruitment of transcriptional co-factors to the
promoter. Indeed, it was previously demonstrated that PAR
can affect protein-protein interaction and assemble multi-
protein complexes (55). Here we specifically show that PAR
regulates protein interactions of p53 in the cell. Thus, PAR
mediates the p53 interaction to Annexin A1, 40S ribosomal
protein S8, zinc-alpha-2-glycoprotein, histone H4, histone
H3 variants or PARP1. Of these, histone H3 and H4 (71),
PARP1 (17) andAnnexin A1 (72) were previously identified
as interaction partners of p53. It will be interesting to
disentangle in future studies to what extent the cellular
effects on p53 function are dependent on non-covalent PAR
binding or/and covalent PARylation.
The CTD is a target for various PTMs, such as
acetylation, ubiquitination, methylation, and neddylation,
mainly modifying its lysines, including those mutated in
p53 PBM4. Thus, it is conceivable that a modification or
an interplay of different modifications can influence and
regulate non-covalent PAR binding as well as covalent
PARylation of p53. Interestingly, while mice carrying a
genetic deletion of the CTD in their TP53 gene exhibit
anemia and bone marrow failure (9,73), mice with aa
exchanges of all lysines to arginines within the CTD show
only a mild phenotype of  -irradiation hypersensitivity
(74). This raises the hypothesis that in such a mutant, the
p53-CTD is still able to bind PAR and to trigger covalent
PARylation due to unaltered positive charge, which could
explain the absence of a severe phenotype.
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